Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Optimized Maintenance Study Treatment

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Apr 30, 2021 12:56pm

359 Views

Post# 33101909

RE:RE:Optimized Maintenance Study Treatment

Only patients 5 & 6 got optimized treatment in PH1 and were CR for at least 18 months.
From PH1 "As previously reported, the Company, in conjunction with its clinical partner, have optimized the clinical procedure of the Study commencing with patient number five, who was enrolled and treated in January 2018. The treatment was well tolerated by the patient, who demonstrated no tumour recurrence or presence of disease at the 90 day clinical and cystoscopy assessment. This patient has met Study endpoints demonstrating achievement of the primary, secondary and exploratory endpoints at 90 days post treatment."

enriquesuave wrote:
I was under the impression that 4 of the 1st set of 12 were due to get a second treatment which was to be an Optimized Procedure, plus all patients from 13 and on. It will all be clear when we have enough patients who have received at least one or 2 optimized treatments and see the CR rate for this group. So far 2 on 2 from PH1 and 2 on 3 from PH2 for patients 13,14 & 15( would probably have been 3 on 3 as patient who sadly passed away was showing negative Urine Cytology at 30 days) . So added together that's 4 on 5 ( would have probably been 5 on 5 IMo). We need to see how many are CR post 2nd optimized treatment given at 180 days. The 9 months data (270 days) 3 months later for these patients as well as 3 and 6 months data next Q for patients 13-18. That may be the tipping point where it will be obvious that an Optimized Treatment could hopefully yield unparalleled results. Just IMO

Eoganacht wrote: Theralase has confirmed that 2 patients have recieved the optimized maintenance study treatment in study 2.

This number was inadvertently left blank on page 6 of the MD&A.